Skip to main content

ESSA Pharma Inc. (EPIX)

NASDAQ: EPIX · Delayed Price · USD
8.85 0.26 (3.03%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap389.26M
Revenue (ttm)n/a
Net Income (ttm)-32.78M
Shares Out43.98M
EPS (ttm)-0.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume192,152
Open8.68
Previous Close8.59
Day's Range8.45 - 8.87
52-Week Range5.40 - 36.00
Beta1.56
AnalystsStrong Buy
Price Target17.77 (+100.8%)
Est. Earnings DateDec 16, 2021

About EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

IndustryBiotechnology
Founded2009
Employees25
Stock ExchangeNASDAQ
Ticker SymbolEPIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ESSA Pharma stock is "Strong Buy." The 12-month stock price forecast is 17.77, which is an increase of 100.76% from the latest price.

Price Target
$17.77
(100.76% upside)
Analyst Consensus: Strong Buy

News

ESSA Pharma to Present at Upcoming September Investor Conferences

VANCOUVER, Canada and HOUSTON, Texas, Aug. 31, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapi...

2 weeks ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021

HOUSTON, Texas and VANCOUVER, Canada, Aug. 16, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie...

1 month ago - PRNewsWire

ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference

HOUSTON, Texas and VANCOUVER, Canada, May 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

3 months ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021

- Presented promising preliminary pharmacokinetic and clinical data on EPI-7386 in metastatic castration-resistant prostate cancer at 2021 AACR - Raised approximately $150 million in a public offering H...

4 months ago - PRNewsWire

ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolut...

HOUSTON, Texas and VANCOUVER, Canada, April 28, 2021 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapi...

4 months ago - PRNewsWire

ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference

HOUSTON, Texas and VANCOUVER, Canada, April 14, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapi...

5 months ago - PRNewsWire

ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Associati...

HOUSTON, Texas and VANCOUVER, Canada, April 10, 2021 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therap...

5 months ago - PRNewsWire

ESSA Announces Change to its Board of Directors

HOUSTON, Texas and VANCOUVER, BC, March 26, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies f...

5 months ago - PRNewsWire

ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing

VANCOUVER, BC and HOUSTON, March 4, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

6 months ago - PRNewsWire

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therap...

6 months ago - PRNewsWire

ESSA Pharma to Present at Upcoming March Investor Conferences

HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapi...

6 months ago - PRNewsWire

ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock

VANCOUVER, BC and HOUSTON, Feb. 22, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

6 months ago - PRNewsWire

ESSA Pharma Announces Pricing of Public Offering of Common Shares

VANCOUVER, BC and HOUSTON, Feb. 17, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

7 months ago - PRNewsWire

ESSA Pharma Announces Proposed Public Offering of Common Shares

VANCOUVER, BC and HOUSTON, Feb. 16, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

7 months ago - PRNewsWire

Why ESSA Pharma, AnaptysBio And More Are Moving Today

ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...

Other symbols:ANABPACB
7 months ago - Benzinga

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate ...

VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

7 months ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020

VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

7 months ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended Septembe...

VANCOUVER and HOUSTON, Dec. 15, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the trea...

9 months ago - PRNewsWire

ESSA Pharma to Participate in Upcoming Investor Conferences

HOUSTON and VANCOUVER, BC, Nov. 10, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the t...

10 months ago - PRNewsWire

ESSA Pharma Inc. Announces Delisting from the TSX-V

HOUSTON and VANCOUVER, BC, Oct. 26, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therap...

10 months ago - PRNewsWire

ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium

HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of pr...

10 months ago - PRNewsWire

ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit

HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel the...

11 months ago - PRNewsWire

ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020

HOUSTON and VANCOUVER, BC, Sept. 17, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of ...

1 year ago - PRNewsWire

ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castratio...

HOUSTON and VANCOUVER, BC, Sept. 14, 2020 /PRNewswire/ - ESSA Pharma Inc.

1 year ago - PRNewsWire

ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor

ESSA's EPI-7386 novel approach to treat prostate cancer by targeting the N-terminal domain androgen receptor inhibitor is now in Phase 1 trials. The first patient was dosed on July 15.

1 year ago - Seeking Alpha